Origins Appeals To NARB Following Case Over Plantscription Claims
This article was originally published in The Rose Sheet
The Estee Lauder Companies’ Origins unit is appealing to NARB after NAD advised the firm to drop or modify claims comparing its Plantscription products to anti-aging prescription cream Renova.
You may also be interested in...
The National Advertising Review Board upholds a NAD ruling that the brand should discontinue claims comparing its Plantscription anti-aging serum to anti-wrinkle prescription products. NARB reversed several other NAD decisions on certain claims for the same product.
The return of the luxury shopper in the U.S. and the strength of the travel retail market provided a significant boost to The Estee Lauder Companies' sales and earnings in the fiscal third quarter, the firm reported during a May 5 earnings call.
Performance claims from University Medical Pharmaceuticals touting the quick-acting effect of its WrinkleFree Eyes and comparing the product to Botox should be discontinued, the National Advertising Division says